Targeted Photodynamic Therapy using a Water-Soluble Aggregation-Induced Emission Photosensitizer Activated by an Acidic Tumor Microenvironment

2021 ◽  
pp. 134327
Author(s):  
Xuehong Min ◽  
Fan Yi ◽  
Xiao-Le Han ◽  
Ming Li ◽  
Qianci Gao ◽  
...  
2016 ◽  
Vol 52 (13) ◽  
pp. 2752-2755 ◽  
Author(s):  
Guorui Jin ◽  
Guangxue Feng ◽  
Wei Qin ◽  
Ben Zhong Tang ◽  
Bin Liu ◽  
...  

We report the design of AIE fluorogen (AIEgen)-based multifunctional organic nanoparticles with surface siRNA decoration for targeted photodynamic therapy and RNA interference therapy.


2017 ◽  
Vol 8 (12) ◽  
pp. 8351-8356 ◽  
Author(s):  
Ajesh P. Thomas ◽  
L. Palanikumar ◽  
M. T. Jeena ◽  
Kibeom Kim ◽  
Ja-Hyoung Ryu

Herein, we introduce an indocyanine derivative (IR-Pyr) that is highly water soluble, exhibiting higher mitochondrial targetability and better photostability than IR-780.


2020 ◽  
Vol 56 (17) ◽  
pp. 2630-2633 ◽  
Author(s):  
Jiabao Zhuang ◽  
Hanxiao Yang ◽  
Yue Li ◽  
Bing Wang ◽  
Nan Li ◽  
...  

Efficient photosensitizers with aggregation-induced emission effects were reported to selectively stain lysosome and Gram-positive bacteria, which further triggered the ablation of cancer cells and bacteria under white light irradiation.


Antibodies ◽  
2019 ◽  
Vol 8 (2) ◽  
pp. 26 ◽  
Author(s):  
Raimond Heukers ◽  
Vida Mashayekhi ◽  
Mercedes Ramirez-Escudero ◽  
Hans de Haard ◽  
Theo Verrips ◽  
...  

Photodynamic therapy (PDT) is an approach that kills (cancer) cells by the local production of toxic reactive oxygen species upon the local illumination of a photosensitizer (PS). The specificity of PDT has been further enhanced by the development of a new water-soluble PS and by the specific delivery of PS via conjugation to tumor-targeting antibodies. To improve tissue penetration and shorten photosensitivity, we have recently introduced nanobodies, also known as VHH (variable domains from the heavy chain of llama heavy chain antibodies), for targeted PDT of cancer cells overexpressing the epidermal growth factor receptor (EGFR). Overexpression and activation of another cancer-related receptor, the hepatocyte growth factor receptor (HGFR, c-Met or Met) is also involved in the progression and metastasis of a large variety of malignancies. In this study we evaluate whether anti-Met VHHs conjugated to PS can also serve as a biopharmaceutical for targeted PDT. VHHs targeting the SEMA (semaphorin-like) subdomain of Met were provided with a C-terminal tag that allowed both straightforward purification from yeast supernatant and directional conjugation to the PS IRDye700DX using maleimide chemistry. The generated anti-Met VHH-PS showed nanomolar binding affinity and, upon illumination, specifically killed MKN45 cells with nanomolar potency. This study shows that Met can also serve as a membrane target for targeted PDT.


2017 ◽  
Vol 496 ◽  
pp. 100-110 ◽  
Author(s):  
Oriol Penon ◽  
María J. Marín ◽  
David A. Russell ◽  
Lluïsa Pérez-García

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 91-91
Author(s):  
Ronny Uzana ◽  
Dina Preise ◽  
Lilach Agemy ◽  
Rachel Elmoalem ◽  
Alexander Brandis ◽  
...  

91 Background: Vascular targeted photodynamic therapy (VTP) based on local sensitization of circulating WST11, a water-soluble derivative of Pd-bacteriochlorophyll, enables effective focal ablation of solid tumors. Highly toxic oxygen radicals are produced in the vascular lumen upon illumination with near infra-red light (755nm), leading to irreversible occlusion of tumor feeding arteries and veins. WST11 clears rapidly from the circulation and does not accumulate in the body, providing high level of safety and minimizing adverse effects. WST11-VTP completed Phase II clinical trials in USA and Phase III in Europe for the treatment of early localized prostate cancer as a first line monotherapy with above 80% complete response rate. Here we evaluate its’ safety and efficacy for the treatment of esophageal cancer aiming at development of clinically translatable treatment protocol. Methods: We developed an orthotopic model in which esophageal cancer cells are implanted in the mid esophagus using endoscopy guided procedure. Established tumors are illuminated with cylindrical diffuser deployed through the custom built endoscopy guided system following infusion of WST11. For assessment of treatment safety and tissue recovery normal esophagus tissue was subjected to WST11-VTP using the same treatment set up. Selectivity and efficacy were evaluated histologically by examining sections of treated tumors and normal esophageal tissues under various treatment conditions. Results: Safety control VTP procedures on healthy esophageal tissues have shown a confined destruction only at the illuminated zone while collateral damage to neighboring tissues was not observed. The impact runs as deep as the muscularis propria without signs of perforation or death as a result of the procedure. The VTP protocol was able to ablate implanted and established tumors as opposed to the control group with light illumination alone without the sensitizer (WST11). Conclusions: VTP could be safely applied to treat esophageal tumors, with transient and mild adverse effects. Importantly, VTP effectively eradicated established esophageal tumors in tested set up that could be translated into a clinical treatment protocol.


Sign in / Sign up

Export Citation Format

Share Document